Nevro (NVRO) Price Target Decreased by 5.65% to 18.16

2d ago, source: Fintel on MSN

The average one-year price target for Nevro (NYSE:NVRO) has been revised to 18.16 / share. This is an decrease of 5.65% from ...

Here's Why You Should Retain Nevro (NVRO) Stock for Now

28d ago, source: Hosted on MSN

Nevro Corp. NVRO is well-poised for growth in the coming quarters, courtesy of its research and development (R&D) edge.The optimism, led by a solid third-quarter 2023 performance and continued ...

Nevro Corp

28d ago, source: U.S. News & World Report

Analysts say these cheap stocks have plenty of upside.

Where Nevro Stands With Analysts

15d ago, source: Benzinga.com

Stay informed and make strategic decisions with our Ratings Table. Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the ...

Truist Financial Reaffirms Their Buy Rating on Edwards Lifesciences (EW)

2d ago, source:

In a report released yesterday, Richard Newitter from Truist Financial maintained a Buy rating on Edwards Lifesciences (EW – Research ...

Terumo Corp 4543

2d ago, source: Morningstar

See how this stock stacks up to its competitors with Morningstar Investor ...

Nevro Corp 1N7

7d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Nevro Corp.

22d ago, source: Wall Street Journal

No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...